SRZN · Surrozen, Inc./De - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $983.0K | - | $10.00M | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $9.33M | - | $7.77M | $6.04M | $6.56M | - | $5.20M | $5.33M | $5.25M | - |
| SG&A | $6.13M | - | $4.09M | $3.96M | $3.98M | - | $3.57M | $3.71M | $3.88M | - |
| Total Operating Expenses | $15.46M | - | $11.87M | $10.00M | $10.53M | - | $8.77M | $9.05M | $9.13M | - |
| D&A | $65.0K | - | - | - | $294.0K | - | - | - | $392.0K | - |
| Operating Income | ($10.46M) | - | ($10.88M) | ($9.02M) | ($9.55M) | - | $1.23M | ($9.05M) | ($9.13M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | - | - | - | - | - | - | - | - |
| Net Income | ($127.50M) | - | ($71.64M) | $39.75M | ($26.97M) | - | ($1.43M) | ($25.26M) | ($8.83M) | - |
| EPS - Basic | ($11.65) | - | ($8.36) | $2.55 | ($7.43) | - | ($0.44) | ($7.99) | ($4.24) | - |
| EPS - Diluted | ($11.65) | - | ($8.36) | $2.55 | ($7.43) | - | ($0.44) | ($7.99) | ($4.24) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $106.91M | $89.25M | $81.33M | $90.39M | $101.64M | $34.56M | $31.01M | $37.77M | $27.29M | $36.04M |
| Accounts Receivable | $5.00M | $0 | $2.32M | $2.32M | $2.13M | $2.04M | $12.20M | $2.11M | $2.13M | $2.15M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $889.0K | $728.0K | $538.0K | $354.0K | $302.0K | $306.0K | $276.0K | $173.0K | $131.0K | $525.0K |
| Current Assets | $113.95M | $91.56M | $85.86M | $94.23M | $106.01M | $38.93M | $45.29M | $41.64M | $32.02M | $41.13M |
| Total Assets | $120.71M | $98.73M | $94.05M | $102.70M | $114.83M | $48.47M | $48.00M | $45.07M | $36.72M | $46.08M |
| Current Liabilities | $9.56M | $9.93M | $6.53M | $5.74M | $10.58M | $7.32M | $6.12M | $5.98M | $6.18M | $7.15M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $398.86M | $286.49M | $117.56M | $55.58M | $109.16M | $69.85M | $42.33M | $39.01M | $6.58M | $8.14M |
| Stockholders' Equity | ($278.15M) | ($187.76M) | ($23.52M) | $47.11M | $5.67M | ($21.38M) | $5.67M | $6.06M | $30.14M | $37.94M |
| Retained Earnings | ($654.79M) | ($527.28M) | ($344.13M) | ($272.48M) | ($312.23M) | ($285.26M) | ($257.22M) | ($255.79M) | ($230.53M) | ($221.69M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($12.49M) | - | - | - | ($9.28M) | - | - | - | ($8.75M) | - |
| Investing Cash Flow | ($120.0K) | - | - | - | ($27.0K) | - | - | - | ($7.0K) | - |
| Financing Cash Flow | $30.28M | - | - | - | $76.39M | - | - | - | $0 | - |
| CapEx | $120.0K | - | - | - | $27.0K | - | - | - | $7.0K | - |
| Free Cash Flow | ($12.62M) | - | - | - | ($9.31M) | - | - | - | ($8.75M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -1063.7% | - | -108.9% | - | - | - | - | - | - | - |
| EBITDA margin | -1057.1% | - | - | - | - | - | - | - | - | - |
| Net margin | -12971.0% | - | -716.4% | - | - | - | - | - | - | - |
| Free cash flow margin | -1283.3% | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.10 | - | - | - | 0.35 | - | - | - | 0.99 | - |
| R&D / Revenue | 948.9% | - | 77.7% | - | - | - | - | - | - | - |
| SG&A / Revenue | 623.4% | - | 40.9% | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -105.6% | - | -76.2% | 38.7% | -23.5% | - | -3.0% | -56.0% | -24.0% | - |
| Return on equity | 45.8% | - | 304.7% | 84.4% | -475.3% | - | -25.3% | -416.7% | -29.3% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 11.91 | 9.22 | 13.15 | 16.41 | 10.02 | 5.32 | 7.40 | 6.96 | 5.18 | 5.75 |
| Quick ratio | 11.91 | 9.22 | 13.15 | 16.41 | 10.02 | 5.32 | 7.40 | 6.96 | 5.18 | 5.75 |
| Cash ratio | 11.18 | 8.99 | 12.46 | 15.74 | 9.61 | 4.73 | 5.07 | 6.31 | 4.42 | 5.04 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -0.43 | -0.53 | -4.00 | 2.18 | 20.24 | -2.27 | 8.47 | 7.44 | 1.22 | 1.21 |
| Liabilities / Assets | 3.30 | 2.90 | 1.25 | 0.54 | 0.95 | 1.44 | 0.88 | 0.87 | 0.18 | 0.18 |
| Efficiency | ||||||||||
| Asset turnover | 0.01 | - | 0.11 | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 1857d | - | 85d | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | 3.5x | - | - | - | - | - | - |
| P / B | - | - | - | 0.0x | 0.0x | - | 6.8x | 5.7x | 0.0x | - |
| P / S | 0.3x | - | 0.0x | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -9.5% | - | - | 0.4% | -4.6% | - | - | 11.9% | 37.4% | - |
| Net income growth (YoY) | -372.8% | - | -4896.0% | - | -205.4% | - | 86.3% | -169.1% | 38.2% | - |
| EPS growth (YoY) | -56.8% | - | -1800.0% | - | -75.2% | - | -29.4% | -2477.4% | -783.3% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -35.6% | - | - | - | -6.3% | - | - | - | 39.6% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | -778.2% | - | 677.2% | -81.2% | - | -87.6% | -89.0% | -52.2% | -50.1% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Surrozen against the 5 most active filers in the same SIC group.